Press
Newsroom
Contact
press@imprimedicine.com
Follow
Download
Press Kit
Featured articles
SynBioBeta
How ImpriMed Turned Nine Years in Veterinary Oncology Into a Human Blood Cancer Business
Read More →
TechCrunch
Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology
Read More →
USA Today
ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment
Read More →
MedCity News
Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator
Read More →
Latest Stories
Button Text
In the News
Button Text
Presentations
Button Text
Press Releases
Button Text
Scientific Publications
Button Text
Video/Podcast Interviews
Presentations
A blood-based classifier for differential diagnosis of feline IBD and enteropathy-associated T-cell lymphoma
Veterinary Cancer Society Annual Conference 2026
Learn More →
Presentations
From Prediction to Practice: Clinical Outcomes, Treatment Economics, and the Evolving Role of AI in Canine Lymphoma Care
Veterinary Cancer Society Annual Conference 2026
Learn More →
Presentations
Retrospective cost analysis of machine learning–guided chemotherapy selection in dogs with relapsed B-cell lymphoma, stratified by prediction-treatment concordance
Veterinary Cancer Society Annual Conference 2026
Learn More →
Presentations
Drug Response Prediction–Guided Treatment Selection Is Associated with Improved Survival and Remission in Canine T-Cell Lymphoma
Veterinary Cancer Society Annual Conference 2026
Learn More →
In the News
How ImpriMed Turned Nine Years in Veterinary Oncology Into a Human Blood Cancer Business
SynBioBeta
Learn More →
Press Releases
ImpriMed CEO Dr. Sungwon Lim Invited to National Cancer Institute Panel on Commercializing Functional Precision Medicine
BusinessWire
Learn More →
Presentations
Flow Cytometry's Prognostic Insights in Canine Lymphoma
ACVIM Forum 2026
Learn More →
Presentations
Harnessing AI, Immunophenotyping, and Drug Sensitivity Testing for Individualized Canine Lymphoma Treatment
ACVIM Forum 2026
Learn More →
Presentations
A Multi-Modal Tool for Differential Diagnosis of Feline IBD and EATL Using Minimally Invasive Specimens
ACVIM Forum 2026
Learn More →
Scientific Publications
Integrating genomic and ex vivo drug sensitivity profiling to predict treatment outcomes in Korean patients with non-Hodgkin lymphoma
Biotechnology and Bioprocess Engineering
Learn More →
Presentations
A multi-omic approach to biomarker discovery for the differential diagnosis of feline IBD and EATL using minimally invasive specimens
Veterinary Cancer Society Collaborative Conference 2025
Learn More →
Scientific Publications
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in acute myeloid leukemia
Biotechnology and Bioprocess Engineering
Learn More →
Scientific Publications
Quantitative ex vivo assessment of chemotherapy synergy using patient-derived non-Hodgkin lymphoma samples
Biotechnology and Bioprocess Engineering
Learn More →
In the News
Health Tech: Valerie Goodwin-Adams of ImpriMed On How Their Technological Innovations Will Shake Up The Tech Scene
Authority Magazine
Learn More →
Presentations
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples
67th ASH Annual Meeting and Exposition
Learn More →
Presentations
Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival
67th ASH Annual Meeting and Exposition
Learn More →
Presentations
A multi-institutional machine-learning score that predicts bacteremia and gram class at blood-culture initiation
67th ASH Annual Meeting and Exposition
Learn More →
Press Releases
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
PR Newswire
Learn More →
Next
Webflow Homepage
Veterinary Precision Medicine
Human Precision Medicine
Ex Vivo CRO Services for Pharma
About Us
Careers
Events
Press
Language
日本語 (Japanese)
English (International)
日本語 (Japanese)
English (International)
Contact Us
